Evolent Level 1 Medical Oncology

Pathways and Low-Value Regimens

Anal Cancer

Regimen Options

Last Updated: 05/31/2024 See Details

	Evolent Pathways	Febrile Neutropenic Risk	Emetogenic Risk	References
NON-METASTATIC
Definitive Chemoradiation	mitomycin and 5FU (fluorouracil)	Low	Low	NCCN Guidelines® for Anal Carcinoma V.1.2017. Flam M, et al. J Clin Oncol. 1996;14(9):2527-39. Ajani JA, et al. JAMA. 2008;299(16):1914-21.
	mitomycin and capecitabine	Low	Low
ADVANCED/METASTATIC
Initial Therapy	carboplatin + paclitaxel	Low	High	NCCN Guidelines® for Anal Carcinoma V.1.2017. Rao S et al. DOI https://doi.org/10. 1200/JCO.19.03266
Subsequent Therapy	Best Supportive Care or Clinical Trial	NCCN Guidelines® for Supportive Care.

NON-METASTATIC

Definitive Chemoradiation

Evolent Pathways

mitomycin and 5FU (fluorouracil)

Febrile Neutropenic Risk

low

Emetogenic Risk

low

References

Evolent Pathways

mitomycin and capecitabine

Febrile Neutropenic Risk

low

Emetogenic Risk

low

ADVANCED/METASTATIC

Initial Therapy

Evolent Pathways

carboplatin + paclitaxel

Febrile Neutropenic Risk

low

Emetogenic Risk

high

References

Subsequent Therapy

Evolent Pathways

Best Supportive Care or Clinical Trial

References